Emerging retatrutide, a dual -action drug targeting both GLP-1 and GIP receptors, is creating considerable excitement within the weight loss community. Preliminary clinical trials have shown significant losses in overall weight and gains in metabolic markers for people with excess weight . Scientists believe this unique approach may signify a ke… Read More